Related Experiment Video
Updated: Aug 30, 2025
04:37
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
607
Platelet Activating Factor (PAF): A Mediator of Inflammation
Julia E M Upton1, Eyal Grunebaum1,2,3, Gordon Sussman4
1Division of Immunology and Allergy, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Biofactors (Oxford, England)
|August 27, 2022
Summary
Platelet-activating factor (PAF) is a key mediator in inflammation, contributing to various diseases. Targeting the PAF pathway offers potential for effective treatments for inflammatory conditions.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Platelet-activating factor (PAF) is a phospholipid mediator involved in inflammatory responses.
- PAF is synthesized by various cells and rapidly degraded by PAF acetylhydrolase to inactive lyso-PAF.
- PAF plays a role in platelet aggregation and activation, and contributes to inflammatory diseases.
Purpose of the Study:
- To review the established and emerging roles of PAF in inflammatory conditions.
- To highlight the significance of the PAF pathway in various diseases and as a potential therapeutic target.
- To discuss the potential of PAF-targeted therapies for managing inflammation.
Main Methods:
- Literature review of studies on PAF's role in inflammation.
- Analysis of animal models and human disease states involving PAF.
- Examination of recent research on PAF's involvement in specific conditions.
Main Results:
- PAF is implicated in anaphylaxis, sepsis, cardiovascular, neurological diseases, and malignancy.
- Emerging research shows PAF's importance in pediatric anaphylaxis, blood-brain barrier permeability, reproduction, and ocular diseases.
- The PAF pathway is being investigated as a biomarker and therapeutic target for inflammation management.
Conclusions:
- The PAF pathway is crucial in numerous inflammatory conditions.
- Targeting the PAF pathway presents a promising strategy for developing effective anti-inflammatory therapies.
- Further investigation into PAF as a biomarker and therapeutic target is warranted.
Related Concept Videos
01:22Formation of the Platelet Plug
7.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.0K
01:18Structure and Function of Platelets
1.4K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.4K
01:16Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
01:38Inflammation
54.8K
Overview
54.8K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
619
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
619
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
863
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
863